Sun Pharma agrees to acquire Checkpoint Therapeutics [Yahoo! Finance]
Fortress Biotech, Inc. (FBIO)
Last fortress biotech, inc. earnings: 11/12 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
fortressbiotech.com
Company Research
Source: Yahoo! Finance
The acquisition is set to add Checkpoint's US Food and Drug Administration (FDA)-approved Unloxcyt (cosibelimab-ipdl) to the global onco-derm franchise of Sun Pharma. Unloxcyt treats metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) in the adult population who are not suitable for curative surgery or radiation. Sun Pharma will purchase Checkpoint's complete outstanding shares. Stockholders of Checkpoint will obtain an upfront cash payment of $4.10 per share and are eligible for a non-transferable contingent value right of up to $0.70 per share if the therapy gains approval by certain dates in the European Union or specific European countries. The transaction will conclude in the second quarter of 2025, subject to regulatory approvals and the affirmative vote of Checkpoint's shareholders. Sun Pharma managing director and chairman Dilip Shanghvi stated: “Combining Unloxcyt, an FDA-approved anti-programmed cell death ligand 1 (PD-L1) treatment for advance
Show less
Read more
Impact Snapshot
Event Time:
FBIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FBIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FBIO alerts
High impacting Fortress Biotech, Inc. news events
Weekly update
A roundup of the hottest topics
FBIO
News
- Fortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA Resubmission [Yahoo! Finance]Yahoo! Finance
- Fortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA ResubmissionGlobeNewswire
- Fortress Biotech (NASDAQ:FBIO) had its "sell (d)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Fortress Biotech (NASDAQ:FBIO) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=FBIO&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street ZMarketBeat
- Fortress Biotech GAAP EPS of $0.11, revenue of $17.6M [Seeking Alpha]Seeking Alpha
FBIO
Sec Filings
- 12/18/25 - Form 424B3
- 12/18/25 - Form EFFECT
- 12/16/25 - Form S-1
- FBIO's page on the SEC website